A new trading day began on Friday, with Cognition Therapeutics Inc (NASDAQ: CGTX) stock price up 5.45% from the previous day of trading, before settling in for the closing price of $1.65. CGTX’s price has ranged from $0.22 to $3.83 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -16.44%. Meanwhile, its annual earnings per share averaged 54.65%. With a float of $80.15 million, this company’s outstanding shares have now reached $88.27 million.
Cognition Therapeutics Inc (CGTX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cognition Therapeutics Inc is 9.20%, while institutional ownership is 17.42%. The most recent insider transaction that took place on Jan 31 ’25, was worth 30,001. In this transaction CEO & President of this company bought 38,851 shares at a rate of $0.77, taking the stock ownership to the 38,851 shares.
Cognition Therapeutics Inc (CGTX) Earnings and Forecasts
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.17 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.06 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 54.65% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 20.63% during the next five years compared to -16.44% drop over the previous five years of trading.
Cognition Therapeutics Inc (NASDAQ: CGTX) Trading Performance Indicators
Here are Cognition Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.44. For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.47, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.34 in one year’s time.
Technical Analysis of Cognition Therapeutics Inc (CGTX)
Looking closely at Cognition Therapeutics Inc (NASDAQ: CGTX), its last 5-days average volume was 0.85 million, which is a drop from its year-to-date volume of 4.18 million. As of the previous 9 days, the stock’s Stochastic %D was 94.59%.
During the past 100 days, Cognition Therapeutics Inc’s (CGTX) raw stochastic average was set at 36.23%, which indicates a significant decrease from 83.77% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1418 in the past 14 days, which was lower than the 0.1980 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.6036, while its 200-day Moving Average is $0.9637. However, in the short run, Cognition Therapeutics Inc’s stock first resistance to watch stands at $1.7883. Second resistance stands at $1.8367. The third major resistance level sits at $1.9083. If the price goes on to break the first support level at $1.6683, it is likely to go to the next support level at $1.5967. Should the price break the second support level, the third support level stands at $1.5483.
Cognition Therapeutics Inc (NASDAQ: CGTX) Key Stats
With a market capitalization of 153.60 million, the company has a total of 88,274K Shares Outstanding. Currently, annual sales are 0 K while annual income is -33,970 K. The company’s previous quarter sales were 0 K while its latest quarter income was -4,930 K.
